Theriva Biologics, Inc. · AMEX:TOVX
Theriva Biologics — Technical Presentation (October 2025)
15 slides from Theriva Biologics's technical presentation, Oct 20, 2025
Slide 1: VIRAGE trial: randomized Phase IIb study of VCN-01 in metastatic pancreatic cancer
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. R.Garcia - Carbonero VIRAGE trial: randomized Phase IIb, open - label, study of Nab - Paclitaxel and Gemcitabine with/without intravenous VCN - 01 in Patients with Metastatic Pancreatic C
Slide 2: Declaration of Interests
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Declaration of Interests R. Garcia - Carbonero Rocio Garcia - Carbonero □ Consultant or Advisory Role: AAA/Novartis, Advanz Pharma, Astellas, Bayer, BMS, Boerhinger , Crinetics , Esteve,
Slide 3: Background: VCN-01
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Background: VCN - 01 R. Garcia - Carbonero VCN - 01 ( zabilugene almadenorepvec ) is an oncolytic adenovirus designed to replicate in cancer cells with a dysfunctional RB 1 pathway and ex
Slide 4: VIRAGE - Design
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. VIRAGE - Design R. Garcia - Carbonero • VIRAGE is a multicenter, open - label, randomized trial for direct comparison of up to 2 doses of VCN - 01 with gem/nab - paclitaxel (SoC) to SoC a
Slide 5: VIRAGE - CONSORT
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. VIRAGE - CONSORT R. Garcia - Carbonero Groups for analysis: x Modified Intent - to - Treat ( mITT ) / Safety population All randomized patients who received any dose of the assigned treat
Slide 6: VIRAGE - Demographics
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. VIRAGE - Demographics R. Garcia - Carbonero FAS mITT VCN - 01 + SoC (n=48) SoC (n=48) VCN - 01 + SoC (n=53) SoC (n=48) 48 48 53 48 n 66.0 (41 - 86) 68.5 (52 - 85) 66.0 (41 - 86) 68.5 (52
Slide 7: Safety: Treatment Emergent AEs (≥10% patients)
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Safety : Treatment Emergent AEs ( ≥10% patients) R. Garcia - Carbonero VCN - 01 + SoC (N=53) n(%) SoC (N=48) n (% ) Preferred Term SOC % Grade≥3 (n) % All grades (n) % Grade ≥3 (n) % All
Slide 8: Safety: VCN-01-related TEAEs (≥5% patients)
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Safety : VCN - 01 - related TEAEs ( ≥5% patients) R. Garcia - Carbonero VCN - 01 Dose 2 (N=36) VCN - 01 Dose 1 (N=53) Preferred Term % Grade ≥3 (n) % All grades (n) % Grade ≥3 (n) % All g
Slide 9: Response Rate, DoR & PFS
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Duration of Response ( DoR ) SoC VCN - 01 + SoC Response Rate, DoR & PFS R. Garcia - Carbonero DCR % ORR (n) PD SD PR CR 34 ( 70.8% ) 15 ( 31.3% ) 14 19 15 0 SoC (n=48) 37 (77.1%) 19 (39.
Slide 10: Primary Endpoint – Overall Survival
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. SoC VCN - 01 + SoC SoC VCN - 01 + SoC Primary Endpoint – Overall Survival R. Garcia - Carbonero VCN - 01+SoC (n=48) SoC (n=48) 10.8 (7.4 - 15.8) 8.6 (6.9 - 11.6) Median (95% CI) months 0.
Slide 11: Preplanned Subgroup Analysis
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Preplanned Subgroup Analysis All patients who started the 4th cycle of SoC (+ 2 doses of VCN - 01 in Arm II) R. Garcia - Carbonero VCN - 01+SoC (n=34) SoC (n=29) VCN - 01+SoC (n=34) SoC (
Slide 12: Results – Biologic Data
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Results – Biologic Data R. Garcia - Carbonero 0 100 200 300 400 500 600 160 640 2,560 10,240 40,960 163,840 Days (since 1st VCN-01 dose) N a b T i t e r ( 1 / x ) VCN - 01 genomes in pati
Slide 13: Conclusions
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Conclusions R. Garcia - Carbonero • VCN - 01 at 1E13 vp /dose combined with gemcitabine/nab - paclitaxel was safe and well tolerated • VCN - 01 - related serious adverse events were trans
Slide 14: Thank you!!!
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Thank you!!! We want to thank all patients, their families, investigators and their study team who participated in VIRAGE trial. R.Garcia - Carbonero
Slide 15: European Society for Medical Oncology (ESMO)
European Society for Medical Oncology (ESMO) Via Ginevra 4, CH - 6900 Lugano T. +41 (0)91 973 19 00 esmo@esmo.org esmo.org
Theriva Biologics — Technical Presentation (October 2025) on 6ix